Restrictive Practice Recommended Consent and Potential Risks Prescribing Person(s) Example Controls Endorsement PBS practitioner: Develops Anti-convulsant Refer to individual Refer to the individual Consent: Person with the PBSP, contributes to the medication product information, product information but capacity to give risk assessment. but may include generally should include: consent or their relative When not prescribed for Medical practitioner/ sedation, causing or guardian. epilepsy management Observation including • psychiatrist (where the swallowing or a relevant psychiatric monitoring for side If the person is restrictive practice is being difficulties diagnosis (for example, effects (when resisting or objecting to used to administer medical (dysphagia), falls bi-polar affective medication commenced, the medication, the treatment): Prescribes the and pressure areas disorder, schizophrenia, increased, or ceased). consent of an medical treatment and leading to ulsers. schizoaffective disorder) appointed guardian Awareness of toxicity • contributes to the PBSP and such as: with relevant powers symptoms. risk assessment as required. as per Section 32 of Carbamazepine • Regular medical review. • Community nurse (where the Guardianship and Sodium Valproate • involved in the Administration Act Lamotrigine. • administration of the is also required. 1993 medical treatment): Endorsement: The Contributes to the PBSP and delegated restrictive the risk assessment as practices compliance required. officer. PBS practitioner: Develops Refer to individual Refer to the individual Anti-histamines Consent: Person with the PBSP, contributes to the product information, product information but capacity to give When prescribed for the risk assessment. but may include: generally would include: consent or their relative principle purpose of Medical practitioner/ or guardian. sedation, for example: Sedation Observation including • • psychiatrist (where the (causing monitoring for side If the person is Phenergan • restrictive practice is being dysphagia, falls effects (when resisting or objecting to Vallergan. • used to administer medical and pressure medication commenced, the medication, the treatment): Prescribes the areas). increased, or ceased). consent of an medical treatment and appointed guardian Awareness of toxicity • contributes to the PBSP and with relevant powers symptoms. risk assessment as required. as per Section 32 of Regular medical review. • Community nurse (where the Guardianship and involved in the
Restrictive Practice Example Potential Risks Recommended Controls Prescribing Person(s) Consent and Endorsement Anti-convulsant medication When not prescribed for epilepsy management or a relevant psychiatric diagnosis (for example, bi-polar affective disorder, schizophrenia, schizoaffective disorder) such as: • Carbamazepine • Sodium Valproate • Lamotrigine. Refer to individual product information, but may include sedation, causing swallowing difficulties (dysphagia), falls and pressure areas leading to ulsers. Refer to the individual product information but generally should include: • Observation including monitoring for side effects (when medication commenced, increased, or ceased). • Awareness of toxicity symptoms. • Regular medical review. PBS practitioner: Develops the PBSP, contributes to the risk assessment. Medical practitioner/ psychiatrist (where the restrictive practice is being used to administer medical treatment): Prescribes the medical treatment and contributes to the PBSP and risk assessment as required. Community nurse (where involved in the administration of the medical treatment): Contributes to the PBSP and the risk assessment as required. Consent: Person with capacity to give consent or their relative or guardian. If the person is resisting or objecting to the medication, the consent of an appointed guardian with relevant powers as per Section 32 of the Guardianship and Administration Act 1993 is also required. Endorsement: The delegated restrictive practices compliance officer. Anti-histamines When prescribed for the principle purpose of sedation, for example: • Phenergan • Vallergan. Refer to individual product information, but may include: • Sedation (causing dysphagia, falls and pressure areas). Refer to the individual product information but generally would include: • Observation including monitoring for side effects (when medication commenced, increased, or ceased). • Awareness of toxicity symptoms. • Regular medical review. PBS practitioner: Develops the PBSP, contributes to the risk assessment. Medical practitioner/ psychiatrist (where the restrictive practice is being used to administer medical treatment): Prescribes the medical treatment and contributes to the PBSP and risk assessment as required. Community nurse (where involved in the Consent: Person with capacity to give consent or their relative or guardian. If the person is resisting or objecting to the medication, the consent of an appointed guardian with relevant powers as per Section 32 of the Guardianship and
restrictive-practices-reference-guide-south-australian-disability-sector.docx